New drug aims to slow kidney damage in IgA nephropathy
NCT ID NCT07474636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an experimental drug called HS-10542 in 90 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either a high dose, low dose, or placebo for a set period. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HS-10542 capsules
- What this could lead to
- If successful, this could point toward a new treatment option to control IgA nephropathy and reduce protein leakage in urine, potentially slowing kidney decline.
- What could go wrong
- This is an early Phase 2 trial with only 90 participants, so results may not apply broadly. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLOMERULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill aims to slow kidney disease in IgA nephropathy patients
- New drug shows promise for kidney disease in phase 2 trial
- New drug combo aims to tame rare kidney diseases
- New drug aims to reduce kidney damage in IgAN patients
- New drug OMS721 tested for rare kidney conditions
- New drug zigakibart aims to slow kidney disease in IgA nephropathy patients